Nomination committee for Aptahem Annual General Meeting 2023

2022-11-28

Aptahem’s nomination committee for the AGM next year has held a meeting. The nomination committee consists of three members represententing the three largest owners as of 30 September this year that wish to appoint a representative to the committee...

Read More

BioStock Studio: Aptahem’s CEO on upcoming milestones

2022-11-24

Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock’s studio to present the company...

Read More

Analyst Group har publicerat en videointervju med VD Mikael Lindstam

2022-11-18

Analyst Group publicerade den 17 november 2022 en videointervju med VD Mikael Lindstam där han kommenterar den nyligen inledda kliniska Fas 1-studien och den förestående företrädesemissionen. Intervjun finns tillgänglig på Analyst Groups webbsida och på www.aptahem.com. För ytterligare information:...

Read More

Idag inleds teckningsperioden i Aptahem AB:s (publ) företrädesemission

2022-11-18

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

Read More

Aptahem informerar om genomförande av klinisk Fas 1-studie

2022-11-17

Aptahem AB (publ), ett bioteknikbolag som utvecklar behandlingar för patienter som drabbas av akuta inflammatoriska sjukdomar så som sepsis, informerar idag kring den uppskattade tidplanen för genomförandet av den kliniska Fas 1-studien (First in Human, FIH) med sin läkemedelskandidat...

Read More

Aptahem AB (publ) offentliggör memorandum avseende företrädesemissionen

2022-11-17

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

Read More

Aptahem receives full regulatory approval to start the FIH study with Apta-1

2022-11-10

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, has today received approval from the central ethics committee and the competent authorities in the Netherlands to start a clinical First...

Read More

BioStock article: Aptahem’s CEO comments on the rights issue

2022-11-10

BioStock published an article on 10 November 2022 about Aptahem, which can be read in full below. Biotechnology company Aptahem’s report for the third quarter of 2022 focuses on the progress made on the way to the major milestone,...

Read More

BioStock article: Aptahem provides an operational update

2022-10-31

BioStock published an article on 31 October 2022 about Aptahem, which can be read in full below. Aptahem is nudging closer to its biggest milestone as a listed biotech company – the first clinical studies with Apta-1, a drug...

Read More

BioStock article: Aptahem on the application to initiate clinical studies

2022-09-26

BioStock published an article on 26 September 2022 about Aptahem, which can be read in full below. Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee in the Netherlands for permission to start a...

Read More